Economic and Clinical Impact of Stroke and Warfarin Use for Patients with Non-valvular Atrial Fibrillation

Li Wang^{1*}, Elyse Fritschel¹, Onur Baser²

¹ STATinMED Research, Dallas, TX, USA

² The University of Michigan and STATinMED Research, Ann Arbor, MI, USA

Corresponding author: lwang@statinmed.com

Abstract

Background: Atrial fibrillation (AF) is a common clinical problem and potent risk factor for stroke. However, real-world effectiveness and outcomes for AF patients are not well described.

Objective: To compare the economic and clinical impact of stroke and warfarin use on patients with non-valvular atrial fibrillation (NVAF).

Methods: This was a retrospective analysis of medical and pharmacy claims of NVAF patients from a large commercial health insurance database (01/01/2005-12/31/2007). Patients were grouped according to stroke or warfarin prescription status. For all groups, demographic, clinical, and pharmaceutical characteristics were analyzed descriptively. Risk-adjusted overall and cardiovascular-related hospital readmission rates in 30 days, length of stay (LOS), clinical outcomes, and health care costs were assessed using propensity score matching. Costs were adjusted to 2007 U.S. dollars using the medical component of the U.S. Consumer Price Index.

Results: Out of 18,575 NVAF patients, 3.1% (n=575) experienced a stroke event. Stroke patients were older on average (78.94 vs. 77.28 years, p-value<0.0001) with significantly higher risk-adjusted inpatient mortality (7.14% vs. 2.09%, p-value<0.0001), emergency room visits (79.97% vs. 46.34%, p-value<0.0001), and average LOS measures (overall: 10.20 vs. 6.83 days, p<0.0001; cardiovascular-related: 8.35 vs. 5.90 days, p-value<0.0001). Despite the similarity in Charlson Comorbidity Index scores compared to non-stroke controls, stroke patients significantly higher clinical outcome rates during follow-up for acute coronary syndrome (ACS), ischemic attack, major and minor bleeding patients (p-values<0.0100), and the total cost incurred was nearly three times greater (\$33,506 vs. \$13,921, p-values<0.0001). NVAF patients were commonly prescribed warfarin (65.60%) and appeared to have a lower prevalence of clinical outcomes, while not incurring significantly higher follow-up costs compared to those not prescribed warfarin (\$12,739, standard deviation [SD]=\$19,842 vs. \$15,358; SD=\$45,446; p-value>0.0500). However, a significantly greater proportion of patients with major and minor bleeding were prescribed a combination of warfarin and antiplatelets than those without these events.

Conclusions: A stroke after an NVAF diagnosis has a major clinical impact, which translates into a significant economic burden for patients. Warfarin prescriptions did not significantly impact total health care costs, though caution is advised to minimize hemorrhagic events.

Keywords: retrospective, NVAF, stroke, cardiovascular, propensity score matching, economic, clinical

INTRODUCTION

Atrial fibrillation (AF) is the most common significant cardiac arrhythmia, affecting an estimated 2.3 million adults in the United States. Its prevalence increases with age, approximately doubling each decade in individuals over age 50 years. In those over age 65 years, AF prevalence is estimated to be 6%¹ and roughly 10% in persons age 80 years or older.^{2,3}

AF patients have six times the risk of ischemic stroke, due to cardiogenic embolism, than age-matched controls, resulting in approximately 80,000 strokes per year in North America.⁴ The risk of stroke in AF patients increases with advancing age and the presence of concomitant risk factors including left ventricular dysfunction, history of hypertension, stroke or transient ischemic attack (TIA), and diabetes mellitus (DM).⁵ Medical therapy has been shown to ameliorate several complications associated with AF, particularly with regard to reducing stroke risk.⁶ Among appropriate diagnosed AF patients, anticoagulation can reduce the risk of a first stroke by approximately 68%,⁷ and it is the recommended therapy in published guidelines.⁸ Therefore, an expert panel has recommended that all AF patients over age 75 should be considered for chronic anticoagulation therapy, unless a contraindication exists.

Elderly patients with an ischemic stroke associated with AF are at especially high risk for a recurrent stroke with an annual rate of more than 10% per year.⁹ Secondary preventative therapy with warfarin is highly effective in reducing this risk. The recurrence rate can be reduced by two thirds with warfarin therapy. Warfarin use was also confirmed to decrease mortality.¹⁰

AF is a common clinical problem and potent risk factor for stroke, yet there is a lack of studies focusing on the real-world effectiveness and safety of outcomes for AF patients.

METHODS

Study Sample

This study used data from a large U.S. commercial database from 2003 to 2008. Table 1 represents patient attrition. The prevalence of stroke was analyzed in selected patients aged 65 years or older with claims for at least two primary diagnoses for AF (determined using the International Classification of Diseases 9th Revision Clinical Modification [ICD-9-CM] codes in Appendix Table A1) occurring within 30 days of one another. Additional criteria for study selection included continuous health plan enrollment for at least 180 days prior to the initial AF diagnosis date (designated as the index date), and the earlier date of at least 180 days following the first AF diagnosis date or until death.

Patients were excluded if they had at least one medical claim for any the following: transient AF caused by a reversible disorder, known presence of atrial myxoma, left ventricular thrombus, active endocarditis, any diagnosis of arterial or venous thromboembolism (VTE), use of selected antiplatelet or anticoagulant agents (low-molecular-weight [LMWH] and unfractionated heparin [UFH], fondaparinux, anisindione, abcximab, cilostazol, anagrelide, pentoxifylline, enoxaparin, dalteparin, or clopidogrel), before the first AF diagnosis. Patients must have had continuous enrollment for at least 180 days before and after the first prescription date. From this final sample (n=19,268), cohorts were assigned; patients were assigned to appropriate cohorts.

Table 1. Attrition Table

Condition	Sample Size
Initial Sample Size	269,339
2 or more AF diagnoses occurring within 30 days of one another	145,938
Age 65 years and older (according to first AF diagnosis date)	140,913
Continuous enrollment for at least 180 days pre-first AF diagnosis date and at least 180 days following first AF diagnosis date or until death, whichever comes first	90,319
AF, atrial myxoma, left ventricular thrombus, active endocarditis, any diagnosis of arterial or VTE, planned cardioversion or trauma diagnose before first AF diagnosis (index) date were excluded.	23,373
Patients prescribed selected antiplatelet or anticoagulant agents (dalteparin, enoxaparin, tinzaparin, heparin sodium in dextrose, heparin sodium, heparin sodium injection, heparin sodium/sodium chloride, fondaparinux, anisindione, abciximab, cilostazol, anagrelide, pentoxifylline) before first diagnosis date were excluded.	19,702
Continuous enrollment for at least 180 days prior to first prescription date and at least 180 days following first prescription date.	19,268
Diagnosed with NVAf	18,575

AF=atrial fibrillation; VTE=venous thromboembolism; NVAf=non-valvular atrial fibrillation

Non-valvular AF (NVAf) patients did not have pre-index claims indicating the presence of transient, perioperative AF, valvular heart disease or concomitant hyperthyroidism or prescriptions for methimazole or propylthiouracil.

Cohort Assignment

NVAf patients were stratified into the following cohorts based on follow-up criteria:

Warfarin or Non-warfarin Cohorts: Patients included in the Warfarin Cohort had at least one prescription for warfarin or dicumarol after the index date, more than one outpatient international normalized ratio (INR) (current procedural terminology [CPT] code: 99211), or a diagnosis or warfarin therapy in the 3 months after initial identified AF diagnosis during the study period, or any combination of these factors. The date of whichever came first was designated as the drug index date; and

Stroke or Non-stroke Cohorts: Stroke Cohort patients had at least one claim for an ischemic or hemorrhagic stroke in the follow-up period (ICD-9-CM codes: 430.xx, 431.xx, 432.xx, 433.xx, 434.xx, 436.0).

COVARIATES AND OUTCOME VARIABLES

Patient Characteristics

Many aspects of health care utilization and cost, including treatment selection, therapy patterns, and health outcomes, may be associated with factors not directly measured in administrative claims data. Vast literature exist demonstrating differences in a variety of health-related outcomes for patients of differing educational

attainment, income, net worth, race and ethnicity and family structure. Therefore, various patient and clinical factors to estimate risk-adjusted comparisons were captured.

Age was defined as of the index date. In addition, patient age was used to assign them to the following age groups: 65-74, 75-84, 85-94, 95+. Median and maximum values were also provided. Gender and U.S. region variables (Northeast, North Central, South, and West) were included as well. The most commonly used comorbidity index in health outcomes studies is the Charlson Comorbidity Index (CCI), which assigns a weight ranging from 1 to 6 according to disease severity for 19 conditions.¹¹ The index has since adopted several weights, some of which allow outpatient diagnoses to contribute to the score.^{12,13}

Comorbid Conditions

The Appendix Table lists disease codes for comorbid conditions and clinical outcomes measured for the baseline period (≥ 180 days pre-index date). Patients were flagged for the following conditions: end stage renal disease (ESRD), congestive heart failure (CHF), peripheral arterial disease (PAD), acute coronary syndrome (ACS), hyperthyroidism, obesity, DM, hypertension, ischemic stroke, hemorrhagic stroke, non-central nervous system (CNS) systemic embolism, TIA, catheter ablation, and dyspepsia. Studied medications included warfarin, injectable anticoagulants (enoxaparin, dalteparin, and fondaparinux), antiplatelets (plavix), and combinations thereof.

Outcome Variables

A flag was created for each of the following variables occurring after the index date (Table 2): in-hospital mortality, average number of health care visits per patient per year (pppy), readmission rates 30 days after discharge, length of stay (LOS) (all-cause and cardiovascular-related), ACS, ischemic stroke, hemorrhagic stroke, TIA, major bleeding, non-major clinically relevant bleeding, non-CNS systemic embolism, surgical ablation, cardioversion, intra-cardiac device, myocardial infarction (MI), osteopathic fracture, intracranial hemorrhage (ICH), and gastrointestinal (GI) bleeding.

Average total annual health care costs per patient were captured as well. Since the analysis is from the payer's perspective, reimbursement amounts rather than charges were applied. Expenditures were expressed in 2007 U.S. dollars and were adjusted using the medical component of the U.S. Consumer Price Index.

STATISTICAL ANALYSIS

Baseline and outcome measures were descriptively analyzed using numbers/percentages for dichotomous and means/standard deviation (SD) for continuous variables. Bivariate comparisons were implemented using t-tests or chi-square tests when appropriate with standardized differences included. Non-parametric tests (e.g. the Mann Whitney U-test) were applied if there was a deviation from asymptotical assumptions.

Multivariate analysis was performed using 1:1 propensity score matching (PSM). Propensity scores were estimated via unconditional logistic regression analysis to yield risk-adjusted estimates (or remove overt bias). Patients were matched if their propensity scores were within ± 0.01 units of one another. Covariates in the logistic regression model included age, gender, baseline CCI score, baseline comorbid conditions, baseline health care utilization, and baseline health care costs. To estimate total cost, a generalized linear model (GLM) with gamma distribution and log link function with cost as the dependent variable and demographic/clinical factors used in PSM as independent variables.

Table 2. Descriptive Statistics for NVAF Patients who did or did not Experience a Stroke

		NVAF Patients (N=18,575)					
		No Stroke (N=18,000)		Stroke (N=575)		P-value	Std Diff
		Mean/N	SD/%	Mean/N	SD/%		
Pre-period (180 days before AF diagnosis date)							
Age (mean)		77.28	7.12	78.94	6.77	0	23.99
Median		77		79			
Maximum		103		96			
65-74		6788	37.71%	152	26.43%	0	24.33
75-84		8161	45.34%	295	51.30%	0.0047	11.95
85-94		2911	16.17%	124	21.57%	0.0006	13.81
95+		140	0.78%	4	0.70%	0.8251	0.96
Gender (Male)		8852	49.18%	275	47.83%	0.5233	2.7
Region							
Northeast		1892	10.51%	50	8.70%	0.1613	6.16
North Central		6372	35.40%	228	39.65%	0.036	8.79
South		4999	27.77%	165	28.70%	0.6266	2.05
West		4720	26.22%	131	22.78%	0.0645	8
Comorbid Conditions							
Elixhauser Index Score (≥2%)		0.06	0.24	0.05	0.21	0.1697	5.52
CCI Score		0.19	0.7	0.22	0.81	0.3459	4.25
ESRD		45	0.25%	4	0.70%	0.0403	6.5
CHF		697	3.87%	13	2.26%	0.0473	9.35
PAD		27	0.15%	3	0.52%	0.0289	6.42
ACS		442	2.46%	11	1.91%	0.4064	3.71
Obesity		10	0.06%	1	0.17%	0.2508	3.49
Diabetes		299	1.66%	9	1.57%	0.8593	0.76
Hypertension		636	3.53%	17	2.96%	0.4597	3.25
Ischemic Stroke		335	1.86%	30	5.22%	0	18.23
Hemorrhagic Stroke		19	0.11%	6	1.04%	0	12.42
TIA		120	0.67%	4	0.70%	0.933	0.35
Catheter Ablation		6	0.03%	0	0.00%	0.6615	2.58
Dyspepsia		6	0.03%	0	0.00%	0.6615	2.58
Pharmacotherapy Pattern (AF diagnosis date – June 2007)							
Warfarin		11818	65.66%	368	64.00%	0.4107	3.47
Injectable Anticoagulant		144	0.80%	2	0.35%	0.2268	5.99
Antiplatelet		545	3.03%	44	7.65%	0	20.67
Other Drug		4764	26.47%	134	23.30%	0.0902	7.32
Other Drug (Antiarrhythmic)		560	3.11%	19	3.30%	0.793	1.1
Other Drug(Rate Control Drugs)		2008	11.16%	61	10.61%	0.6816	1.76
No Medication		729	4.05%	27	4.70%	0.4405	3.16
Warfarin and Anticoagulant		793	4.41%	37	6.43%	0.0204	8.97
Warfarin and Antiarrhythmic		3358	18.66%	117	20.35%	0.3057	4.27
Warfarin and Antiplatelets		516	2.87%	29	5.04%	0.0023	11.18
Warfarin and Rate Control		9691	53.84%	300	52.17%	0.4305	3.33
Warfarin and Antidepressants		399	2.22%	20	3.48%	0.0449	7.59

NVAF=non-valvular atrial fibrillation; SD=standard deviation; AF=atrial fibrillation; CCI=Charlson comorbidity index ESRD=end-stage renal disease; CHF=congestive heart failure; PAD=peripheral arterial disease; ACS=acute coronary syndrome; TIA=transient ischemic attack

Multivariate analysis was performed using 1:1 propensity score matching (PSM). Propensity scores were estimated via unconditional logistic regression analysis to yield risk-adjusted estimates (or remove overt bias). Patients were matched if their propensity scores were within ± 0.01 units of one another. Covariates in the logistic regression model included age, gender, baseline CCI score, baseline comorbid conditions, baseline health care utilization, and baseline health care costs. To estimate total cost, a generalized linear model (GLM) with gamma distribution and log link function with cost as the dependent variable and demographic/clinical factors used in PSM as independent variables.

RESULTS

Stroke vs. Non-stroke Cohorts

Of all NVAf patients, 3.10% experienced a stroke during the study period ($n=575$, Table 2). These stroke-experienced patients were older on average (78.94 vs. 77.28 years, $p\text{-value}<0.0001$) and had higher frequencies of ESRD (0.70% vs. 0.25%, $p\text{-value}=0.040$), PAD (0.52% vs. 0.15%, $p\text{-value}=0.029$), but lower frequency of CHF (2.26% vs. 3.87%, $p\text{-value}=0.047$) relative to those who did not suffer a stroke prior to NVAf diagnosis. Stroke-experienced patients were more frequently prescribed antiplatelets (7.65% vs. 3.03%, $p\text{-value}<0.0001$) or warfarin combinations with either anticoagulants (6.43% vs. 4.41%, $p\text{-value}=0.020$) or antiplatelets (5.04% vs. 2.87%, $p\text{-value}=0.002$) compared to non-stroke patients.

After PSM (Table 3), stroke patients had significantly higher risk-adjusted rates of inpatient mortality (7.14% vs. 2.09%, $p\text{-value}<0.0001$), emergency room (ER) visits (79.97% vs. 46.34%, $p\text{-value}<0.0001$), and average LOS measures (overall: 10.20 vs. 6.83 days, $p\text{-value}<0.0001$; cardiovascular-related: 8.35 vs. 5.90 days, $p\text{-value}<0.0001$). Significantly higher average clinical outcome rates per 100 pppy also occurred for the following conditions: ACS (14.98 vs. 5.57, $p\text{-value}=0.0003$), TIA (25.44 vs. 1.39, $p\text{-value}<0.0001$), major bleeding (29.62 vs. 1.39, $p\text{-value}<0.0001$) and minor bleeding (18.82 vs. 4.18, $p\text{-value}<0.0001$). Many post-index period comorbid conditions (ESRD, CHF, PAD, DM, hypertension) were more common in stroke patients as well. Consistent with the high adverse event rates and complex comorbidity profile, patients who experienced a stroke had health care costs nearly three times greater than patients who did not experience a stroke (\$33,506 vs. \$13,921, $p\text{-value}<0.0001$).

Table 3. Risk-adjusted Outcomes for NVAF Patients who did or did not Experience Stroke

	After Match N=574 for Each Group					
	No Stroke		Stroke		P-value	Std Diff
	Mean/N	SD/%	Mean/N	SD/%		
Mortality-Inpatient	12	2.09%	41	7.14%	<0.0001	24.23
# Patients with Inpatient Visit	255	44.43%	574	100.00%	<0.0001	158.04
# Patients with ER Visit	266	46.34%	459	79.97%	<0.0001	74.30
# Patients with Outpatient Visit	541	94.25%	532	92.68%	0.2786	6.34
# Patients with INR Visit	143	24.91%	111	19.34%	0.0223	13.45
Readmission Rate (30 days)	0	0.00%	10	1.74%	<0.0001	18.81
LOS	7.11	10.7	10.05	12.25	<0.0001	25.60
Cardiovascular-related						
Readmission Rate (30 days)	0	0.00%	10	1.74%	<0.0001	18.81
LOS	5.9	6.98	8.35	9.53	<0.0001	29.34
Clinical Outcomes (100 person-years)						
ACS	16	5.57	43	14.98	0.0003	21.41
TIA	4	1.39	73	25.44	<0.0001	49.46
Major Bleeding	4	1.39	85	29.62	<0.0001	54.66
Non-major Clinical Relevant Bleeding	12	4.18	54	18.82	<0.0001	31.80
Non-CNS Systemic Embolism	4	1.39	8	2.79	0.2482	6.85
Stroke or Non-CNS Systemic Embolism	4	1.39	574	200.00	<0.0001	1686.72
Catheter Ablation	2	0.70	4	1.39	0.4142	4.83
PCI	2	0.70	2	0.70	1.0000	0.00
CABG Surgery	1	0.35	13	4.53	0.0013	19.12
MI	9	3.14	32	11.15	0.0002	21.70
Osteoporotic Fracture	4	1.39	16	5.57	0.0073	16.02
Dyspepsia	0	0.00	3	1.05	<0.0001	10.24
ICH	0	0.00	77	26.83	<0.0001	55.62
GI Bleeding	3	1.05	7	2.44	0.1573	7.50
Health Care Cost						
Total Health Care Costs	\$16,375	\$65,996	\$33,430	\$55,050	<0.0001	28.06

SD=standard deviation; INR=international normalized ratio; LOS=length of stay; ACS=acute coronary syndrome; TIA=transient ischemic attack; CNS=central nervous system; PCI=percutaneous coronary intervention; CABG=coronary artery bypass graft; MI=myocardial infarction; ICH=intracranial hemorrhage; GI=gastrointestinal

NVAF Patients with/without Warfarin Prescription

Among 18,575 patients with NVAF, 12,816 were included in the Warfarin Cohort and 6,389 were in the Non-warfarin Cohort (Table 4). The Warfarin Cohort was relatively young (76.64 vs. 78.65 years, p -value<0.0001) and healthy, with a lower CCI index score (0.15 vs. 0.27, p -value<0.0001) and lower proportion of patients with nearly all comorbid conditions except hyperthyroidism, obesity, non-CNS systemic embolism, catheter ablation, or dyspepsia (p -values>0.0500). The resulting unadjusted total health care costs were lower for patients prescribed warfarin (\$13,906, SD=\$27,285 vs. \$15,712, SD=\$44,832; p -value=0.0033). Since these measures are confounded with baseline characteristics, PSM was applied.

Table 4. Descriptive Statistics for NVAF Patients Prescribed Warfarin or Not

		NVAF Patients (N=18,575)					
		Non-warfarin Cohort		Warfarin Cohort		P-value	Std Diff
		(N=6,389)		(N=12,186)			
		Mean/N	SD/%	Mean/N	SD/%		
Pre-period (180 days pre-AF diagnosis date)							
Age (mean)		78.65	7.77	76.64	6.64	0	27.8
Median		79		76			
Maximum		102		103			
65-74		2,103	32.92%	4,837	39.69%	0	14.13
75-84		2,699	42.24%	5,757	47.24%	0	10.06
85-94		1,480	23.16%	1,555	12.76%	0	27.35
95+		107	1.67%	37	0.30%	0	13.89
Gender (Male)		2,864	44.83%	6,263	51.40%	0	13.17
Region							
Northeast		654	10.24%	1,288	10.57%	0.4808	1.09
North Central		2,217	34.70%	4,383	35.97%	0.0865	2.65
South		1,808	28.30%	3,356	27.54%	0.2728	1.69
West		1,701	26.62%	3,150	25.85%	0.2536	1.76
Comorbid Conditions							
CCI Score		0.27	0.86	0.15	0.61	0	16.66
ESRD		27	0.42%	22	0.18%	0.0022	4.42
CHF		300	4.70%	410	3.36%	0	6.77
PAD		18	0.28%	12	0.10%	0.0031	4.21
ACS		179	2.80%	274	2.25%	0.0202	3.53
Obesity		3	0.05%	8	0.07%	0.6189	0.79
Diabetes		131	2.05%	177	1.45%	0.0024	4.56
MI		93	1.46%	120	0.98%	0.0042	4.29
Hypertension		296	4.63%	357	2.93%	0	8.94
Ischemic Stroke		159	2.49%	206	1.69%	0.0002	5.58
Hemorrhagic Stroke		20	0.31%	5	0.04%	0	6.47
TIA		56	0.88%	68	0.56%	0.0113	3.77
Catheter Ablation		0	0.00%	6	0.05%	0.0761	3.14
Dyspepsia		1	0.02%	5	0.04%	0.3605	1.51
Pharmacotherapy Pattern (AF diagnosis date - June 2007)							
Warfarin		0	0.00%	12,186	100.00%	0	0
Injectable Anticoagulant		146	2.29%	0	0.00%	0	21.63
Antiplatelet		589	9.22%	0	0.00%	0	45.06
Other Drug		4,898	76.66%	0	0.00%	0	256.3
Other Drug (Rate Control Drugs)		2,069	32.38%	0	0.00%	0	97.86
No Medication		756	11.83%	0	0.00%	0	51.81
Warfarin and Anticoagulant		0	0.00%	830	6.81%	0	38.23
Warfarin and Antiarrhythmic		0	0.00%	3,475	28.52%	0	89.32
Warfarin and Antiplatelets		0	0.00%	545	4.47%	0	30.6
Warfarin and Rate Control		0	0.00%	9,991	81.99%	0	301.71

NVAF=non-valvular atrial fibrillation; SD=standard deviation; AF=atrial fibrillation; CCI=Charlson comorbidity index; ERD=end-stage renal disease; CHF=congestive heart failure; PAD=peripheral arterial disease; ACS=acute coronary syndrome; MI=myocardial infarction; TIA=transient ischemic attack

After matching, the adjusted outcomes of 5,966 warfarin and non-warfarin control patients were compared. Warfarin patient in-hospital mortality (0.75% vs. 2.26%, p -value<0.0001) and ER visit rates (48.79% vs. 53.30%, p -value<0.0001) and average cardiovascular-related hospital LOS (5.81 vs. 5.84 days, p -value<0.0001) were lower than those of the matched controls (Table 5). While the rates of clinical outcomes per 100 pppy were generally similar, warfarin patients had lower rates of ACS (3.52 vs. 5.16, p -value=0.0022) and MI (2.04 vs. 3.75, p -value<0.0001) and a higher rate of TIA (2.15 vs. 1.41, p -value=0.033) compared to non-warfarin patients. The resulting health care costs for warfarin and non-warfarin patients was similar after risk adjustment (\$12,739, SD=\$19,842 vs. \$15,358, SD=\$45,446; p -value>0.0500). In the post-index period, warfarin patients had higher follow-up rates of CHF (21.25 vs. 17.40, p -value=0.0003) but lower rates of ESRD (0.64 vs. 1.64, p -value=0.0003).

Table 5. Risk-adjusted Outcomes for NVAf Patients Prescribed Warfarin or Not

	After Match N=5,966 for each Cohort					
	Non Warfarin Cohort		Warfarin Cohort		P-value	SD
	Mean/N	SD/%	Mean/N	SD/%		
Mortality-Inpatient	135	2.26%	45	0.75%	<0.0001	12.4
# Patients with Inpatient Visit	2615	43.83%	2706	45.36%	0.0913	3.07
# Patients with ER Visit	3180	53.30%	2911	48.79%	<0.0001	9.03
# Patients with Outpatient Visit	5428	90.98%	5842	97.92%	<0.0001	30.67
# Patients with INR Visit	340	5.70%	2197	36.83%	<0.0001	82.25
Readmission Rate (30 days)	22	0.37%	18	0.30%	0.5271	1.16
LOS	7.76	13.88	6.54	7.92	0.066	10.75
Cardiovascular-related						
Readmission Rate (30 days)	12	0.20%	16	0.27%	0.4497	1.39
LOS	5.84	8.51	5.81	6.1	<0.0001	0.47
Clinical Outcomes (100 person-years)						
ACS	154	5.16	105	3.52	0.0022	5.64
Ischemic Stroke	167	5.6	178	5.97	0.5502	1.1
Hemorrhage Stroke	33	1.11	23	0.77	0.1814	2.45
TIA	42	1.41	64	2.15	0.0326	3.93
Major Bleeding	75	2.51	88	2.95	0.3026	1.88
Non-major Clinical Relevant Bleeding	148	4.96	137	4.59	0.5102	1.21
Non-CNS Systemic Embolism	37	1.24	48	1.61	0.2328	2.19
Stroke or Non-CNS Systemic Embolism	225	7.54	234	7.84	0.6703	0.78
Catheter Ablation	25	0.84	38	1.27	0.1015	3.01
PCI	45	1.51	29	0.97	0.0593	3.42
CABG Surgery	14	0.47	9	0.3	0.2971	1.91
MI	112	3.75	61	2.04	<0.0001	7.16
Osteoporotic Fracture	65	2.18	45	1.51	0.0565	3.51
Dyspepsia	5	0.17	2	0.07	0.2568	2.08
ICH	37	1.24	26	0.87	0.1658	2.54
GI Bleeding	32	1.07	49	1.64	0.0589	3.47
Health Care Costs						
Total Health Care Costs	\$15,359	\$45,446	\$12,739	\$19,842	0.3704	7.47

SD=standard deviation; INR=international normalized ratio; LOS=length of stay; ACS=acute coronary syndrome; TIA=transient ischemic attack; CNS=central nervous system; PCI=percutaneous coronary intervention; CABG=coronary artery bypass graft; MI=myocardial infarction; ICH=intracranial hemorrhage; GI=gastrointestinal

NVAF Patient Pharmacotherapy Patterns with Adverse Outcomes

NVAF patients with major bleeding (n=266) were prescribed warfarin plus antiplatelet combinations (6.02% vs. 2.89%, p-value=0.0027) significantly more often than those without major bleeding (n=18,309) (Table 6). Similarly, when NVAF patients with non-major bleeding (n=454) were compared to controls lacking non-major bleeding (n=18,121), more non-major bleeding patients were prescribed warfarin+antiplatelets after an AF diagnosis (4.63% vs. 2.89%, p-value=0.0306).

NVAF patients diagnosed with GI bleeding (n=145) were prescribed warfarin significantly more often than the 18,430 patients without GI bleeding (74.48% vs. 65.53%, p-value=0.0239). However, no significant difference was found when comparing warfarin+antiplatelet prescriptions (5.52% vs. 2.91%, p-value=0.0643). NVAF patients who experienced ICH (n=84) were prescribed warfarin alone less often than the 18,491 patients without ICH (53.57% vs. 65.66%, p-value=0.0200), and despite a higher absolute frequency of ICH patients with warfarin+antiplatelet prescriptions (5.95% vs. 2.92%, p-value=0.1004), the difference was not statistically significant.

Table 6. Pharmacotherapy Patterns for Patients with Bleeding/Hemorrhagic Outcomes after AF Diagnosis

Non-major Bleeding (%)			GI Bleeding (%)			ICH (%)		
Yes (n=454)	No (n=18,121)	P-value	Yes (n=145)	No (n=18,430)	P-value	Yes (n=84)	No (n=18,491)	P-value
63.66	65.65	0.3764	74.48	65.53	0.0239	53.57	65.66	0.02
4.63	2.89	0.0306	5.52	2.91	0.0643	5.95	2.92	0.1004

GI=gastrointestinal; ICH=intracranial hemorrhage

DISCUSSION

Stroke in NVAF patients is a clinically relevant event with increased spending implications in Medicare Supplemental patients. Warfarin was commonly prescribed to NVAF patients without a significant increase in total health care expenses. Consideration of the dose intensity of warfarin may help avoid hemorrhagic complications.

An established adverse event associated with warfarin use is hemorrhage, particularly when in combination with antiplatelets.^{14,15} Observational data from this study generally support this claim; a significantly greater proportion of patients with major and minor bleeding were prescribed a combination of warfarin and antiplatelets than those without these events. Absolute frequencies of warfarin and antiplatelet use were higher in GI bleeding and ICH patients, though their small sample sizes may have contributed to the lack of statistical significance, compared to controls without these conditions. These considerations should be kept in mind when creating an optimal treatment plan for NVAF patients.

A major strength of this study involves the use of a large database of nationwide, physician-designated hospital diagnoses with real-world spending figures from a recent time period. While claims data are extremely valuable for the efficient and effective examination of health care outcomes, treatment patterns, and costs, claims data are collected for the purpose of payment and not research. Therefore, there are certain limitations associated with the use of claims data. The presence of a claim for a filled prescription does not indicate that the medication was consumed or that it was taken as prescribed. Additionally, the presence of a diagnosis code on a medical claim is not positive presence of disease, as the diagnosis code may be incorrectly coded or included as rule-out criteria rather than actual disease. Finally, certain information is not readily available in claims

data that could have an effect on study outcomes, such as clinical and disease-specific parameters.

It should be noted that neither regression adjustment addresses problems due to imbalances in unmeasured factors. It is quite possible that outcomes for patients with the same observable characteristics can vary because of unobservable factors such as physician or practice-prescribing patterns. There are several methods that exist to control for unmeasured factors such as the instrumental variable approach, bounding approach and a difference-in-difference estimator. However, these estimators are also confounded by their own limitations.

CONCLUSIONS

A stroke after an NVAf diagnosis has a major clinical and economic impact on patients. Stroke-experienced patients had higher average clinical outcome rates than non-stroke controls as well as more frequent health care resource use (ER visits and longer average hospital LOS) and higher inpatient mortality. These factors contributed to annual total health care costs for stroke-experienced patients nearly three times greater than for those who did not experience a stroke.

Stroke incidence is nearly 5-fold higher in AF patients, so diagnosed patients must be monitored carefully and provided with appropriate pharmacotherapy to avert stroke events.^{16,17} NVAf patients were commonly prescribed warfarin and appear to have a lower prevalence of clinical outcome conditions, while not incurring significantly higher follow-up costs compared to those not prescribed warfarin.

It should be noted that warfarin patients were also younger than controls on average and had a less complex comorbidity profile than patients without a warfarin prescription. Additional research would be necessary to confirm and explain the real-world outcomes seen in this population in a causative manner.

CONFLICT OF INTEREST DECLARATION

The authors declare that they have no competing interests.

REFERENCES

- ¹ Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. *Arch Intern Med* 1995;155:469-73.
- ² Chugh SS, Blackshear JL, Shen WK, et al. Epidemiology and natural history of atrial fibrillation: clinical implications. *J Am Coll Cardiol* 2001;37(2):371-8.
- ³ Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors In Atria Fibrillation (ATRIA) Study. *JAMA*. 2001;285(18):2370-5.
- ⁴ Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. *Arch Intern Med* 1987;147(9):1561-4.
- ⁵ Albers GW, Dalen JE, Laupacis A, et al. Antithrombotic therapy in atrial fibrillation. *Chest* 2001;119(1 suppl):194S-206S.
- ⁶ Fuster V, Ryden LE, Asinger RW, et al. American College of Cardiology/American Heart Association/ European Society of Cardiology Board. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology. *J Am Coll Cardiol* 2001;38(4):1231-66.
- ⁷ Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. *Arch Intern Med* 1994;154(13):1449-57.
- ⁸ Helgason CM, Wolf PA: American Heart Association Prevention Conference IV: prevention and rehabilitation of stroke—executive summary. *Circulation* 1997;96(2):701-7.
- ⁹ Jørgensen HS, Nakayama H, Reith J, et al. Stroke recurrence: predictors, severity, and prognosis—The Copenhagen Stroke Study. *Neurology* 1997;48(4):891-5.
- ¹⁰ Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. *Arch Intern Med* 1998;158(3):229-34.
- ¹¹ Charlson M, Szatrowski TP, Peterson J, Gold J: Validation of a combined comorbidity index. *J Clin Epidemiol* 1994;47(11):1245-51.
- ¹² de Groot V, Beckerman H, Lankhorst GJ, Bouter LM: How to measure comorbidity a critical review of available methods. *J Clin Epidemiol* 2003;56(3):221-9.
- ¹³ Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. *J Clin Epidemiol* 1992;45(6):613-9.
- ¹⁴ Horton JD, Bushwick BM: Warfarin therapy: evolving strategies in anticoagulation. *Am Fam Physician* 1999;59(3):635-46
- ¹⁵ Delaney JA, Opatrny L, Prophy JM, Suissa S. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. *CMAJ* 2007;177(4):347-51.
- ¹⁶ Yamaguchi T: Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation. *Stroke* 2000;31:817-21.
- ¹⁷ EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. *Lancet* 1993;342:1255-62.